Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220098 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of TAK-280 in Participants With Solid Tumors
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT05220098 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 69 participants.
The verdict
NCT05220098, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 treatment cycles. Each treatment cycle will be 28 days. After the last dose of study drug, participants will be followed up for survival every 12 weeks for a total of 48 weeks.
Interventions
- DRUG TAK-280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-04-21 |
| Est. Completion | 2025-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220098
The ClinicalTrials.gov registry entry for NCT05220098 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-280 is the first listed.
NCT05220098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05220098 about?
NCT05220098 is a clinical study titled "First-in-Human Study of TAK-280 in Participants With Solid Tumors". The main aim of this study is to find out the safety, tolerability, and effect of TAK- 280 in participants with unresectable, locally advanced or metastatic cancer who have experienced treatment failure or are intolerant to standard therapies. Participants will be treated with TAK-280 for up to 14 ...
What is the current status of trial NCT05220098?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2022-04-21. Estimated completion is 2025-07-28.
What interventions are being tested in trial NCT05220098?
The interventions under investigation include: TAK-280 (DRUG).
Who is sponsoring clinical trial NCT05220098?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.